Back to eLearning

eLearning

4.02 | QLD OPIOID TREATMENT PROGRAM - Buprenorphine-naloxone and long-acting injection buprenorphine prescriber training

eLEARNING SERIESQLD OPIOID TREATMENT PROGRAM
MODULE NAMEBuprenorphine-naloxone and long-acting injection buprenorphine prescriber training
MODULE NUMBERModule 2 of 4
LEARNING LEVELLevel 4 – AOD Treatment Specific
TARGET AUDIENCEProspective QOTP prescribers (medical and nurse practitioners only)
MODULE AIMThis module aims to equip the learner with the knowledge required to safely and effectively prescribe and administer sublingual buprenorphine-naloxone (Suboxone®) and long acting injection buprenorphine (Buvidal® and Sublocade®) for the treatment of opioid dependence.
LEARNING OUTCOMES

By the end of this module, learners will be able to:

  • describe the pharmacology of buprenorphine-naloxone and long acting injection buprenorphine and identify suitable patients
  • initiate treatment with these formulations

  • manage patients prescribed buprenorphine-naloxone and long acting injection buprenorphine including commencing dose reductions and treatment withdrawal

    NB: This is the second module in the QOTP prescriber course which requires successful completion in order to apply for approval as a Level 2 QOTP prescriber in Queensland, whereby you can then apply to prescribe buprenorphine-naloxone and long acting injection buprenorphine formulations to patients. Do not commence this module if you have not already completed the first QOTP module ("Understanding opioid dependence, assessment and treatment") as this module builds upon knowledge and theories contained within this previous course.

    Further completion of a third module "Buprenorphine-mono and methadone prescriber training" followed by a clinical placement shadowing an existing Level 1 prescriber - is required in order to become a 'Level 1 Full QOTP Prescriber', whereby you can prescribe all opioid dependence treatment medications available in Queensland.

LENGTH1 hour
CPD

This module is accredited for:

  • 0.5 hours of Educational Activities and 0.5 hours of Reviewing Performance with RACGP; and

  • 1 hours of CPD with ACRRM. 

    Please refer to your Statement of Completion for full details.

    NB: Insight uploads CPD hours quarterly to ACRRM and RACGP.

REFERENCE LISTClick here to download the reference list for this module.
SUGGESTED CITATIONInsight: Centre for AOD Training and Workforce Development. QLD Opioid Treatment Program: Buprenorphine-naloxone and long-acting injection buprenorphine prescriber training. Brisbane: Queensland Health; 2025. Available from: https://insight.qld.edu.au/training/elearning
COPYRIGHT INFORMATIONThis resource is licensed under Attribution-NoDerivatives 4.0 International (CC BY-ND 4.0). This license requires that reusers give credit to the creator. It allows reusers to copy and distribute the material in any medium or format in unadapted form only, even for commercial purposes.
LAST UPDATEDAugust 2023
REVIEW AND FEEDBACKAs part of our commitment to continuous quality improvement our eLearning modules undergo a minor review every 2 years, and a major review every 4 years. All evaluation responses are carefully considered during these reviews.  If you have significant or urgent feedback, we encourage you to email us directly at insight@health.qld.gov.au